Xianchao Sun

Xianchao Sun

Auto-generated profile, based on publicly available information

Xianchao Sun

Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230032, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XSXianchao Sun
Xianchao Sun
YZYing Zhang
Ying Zhang
YCYilai Chen
Yilai Chen
SXShiyong Xin
Shiyong Xin
LJLiang Jin
Liang Jin
LYLin Ye
Lin Ye
Background. Aberrant lipid metabolism is an alteration common to many types of cancer. Dysregulation of lipid metabolism is considered a major risk factor for bladder cancer. Accordingly, we focused on genes related to lipid metabolism and screened novel markers for predicting the prognosis of bladder cancer. Methods. RNA‐seq data for bladder cancer were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The nonnegative matrix factorization (NMF) algorithm was used to classify the molecular subtypes. Weighted correlation network analysis (WGCNA) was applied to identify coexpressed genes, and least absolute shrinkage and selection operator (LASSO) multivariate Cox analysis was used to construct a prognostic risk model. External validation data and in vitro experiments were used to verify the results from in silico analysis. Results. Bladder cancer samples were grouped into two clusters based on the NMF algorithm. A total of 1467 genes involved in coexpression modules were identified in WGCNA. We finally established a 5‐gene signature (TM4SF1, KCNK5, FASN, IMPDH1, and KCNJ15) that exhibited good stability across different datasets and was also an independent risk factor for prognosis. Furthermore, the predictive efficacy of our model was generally higher than the predictive efficacy of other published models. Distinct risk groups of patients also showed significantly different immune infiltration cell patterns and associations with clinical variables. Moreover, the 5 signature genes were verified in clinical samples by quantitative real‐time polymerase chain reaction (qRT‐PCR) and immunohistochemistry, which were in agreement with the in silico analysis. For in vitro experiments, knockdown of IMPDH1 markedly inhibited cell proliferation in bladder cancer. Conclusion. We established a 5‐gene prognosis signature based on lipid metabolism in bladder cancer, which could be an effective prognostic indicator.

5 September 2022 in Journal of Oncology
Verified
Journal Article
Open access
YZYing Zhang
Ying Zhang
XKXiangyu Kong
Xiangyu Kong
SXShiyong Xin
Shiyong Xin
LBLiangkuan Bi
Liangkuan Bi
XSXianchao Sun
Xianchao Sun
Discovery of Lipid Metabolism-Related Genes for Predicting Tumor Immune Microenvironment Status and Prognosis in Prostate Cancer: Background. Reprogramming of lipid metabolism is closely associated with tumor development, serving as a common and critical metabolic feature that emerges during tumor evolution. Meanwhile, immune cells in the tumor microenvironment also undergo aberrant lipid metabolism, and altered lipid metabolism also has an impact on the function and status of immune cells, further promoting malignant biological behavior. Consequently, we focused on lipid metabolism-related genes for constructing a novel prognostic marker and evaluating immune status in prostate cancer. Methods. Information about prostate cancer patients was obtained from TCGA and GEO databases. The NMF algorithm was conducted to identify the molecular subtypes. The least absolute shrinkage and selection operator (Lasso) regression analysis was applied to establish a prognostic risk signature. CIBERSORT algorithm was used to calculate immune cell infiltration levels in prostate cancer. External clinical validation data were used to validate the results. Results. Prostate cancer samples were divided into two subtypes according to the NMF algorithm. A six-gene risk signature (PTGS2, SGPP2, ALB, PLA2G2A, SRD5A2, and SLC2A4) was independent of prognosis and showed good stability. There were significant differences between risk groups of patients with respect to the infiltration of immune cells and clinical variables. Response to immunotherapy also differed between different risk groups. Furthermore, the mRNA expression levels of the signature genes were verified in tissue samples by qRT-PCR. Conclusion. We constructed a six-gene signature with lipid metabolism in prostate cancer to effectively predict prognosis and reflect immune microenvironment status.

13 May 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
WMWangli Mei
Wangli Mei
XJXuyang Jia
Xuyang Jia
SXShiyong Xin
Shiyong Xin
XLXiang Liu
Xiang Liu
LJLiang Jin
Liang Jin
LYLin Ye
Lin Ye
Background. Despite the constant iteration of small-molecule inhibitors and immune checkpoint inhibitors, PRAD (prostate adenocarcinoma) patients with distant metastases and biochemical recurrence maintain a poor survival outcome along with an increasing morbidity in recent years. N7-Methylguanine, a new-found type of RNA modification, has demonstrated an essential role in tumor progression but has hardly been studied for its effect on prostate carcinoma. The current study aimed to seek m7G (N7-methylguanosine) related prognostic biomarkers and potential targets for PRAD treatment. Methods. 42 genes related to m7G were collected from former literatures and GSEA (Gene Set Enrichment Analysis) website. Then, RNA-seq (RNA sequencing) and clinical data from TCGA-PRAD (The Cancer Genome Atlas-Prostate) cohort were retrieved to screen the differentially expressed m7G genes to further construct a multivariate Cox prognostic model for PRAD. Next, GSE116918, a prostate cancer cohort acquired from GEO (Gene Expression Omnibus) database, was analyzed for the external validation group to assess the ability to predict BFFS (biochemical failure-free survival) of our m7G prognostic signature. Kaplan-Meier, ROC (receiver operator characteristic), AUC (areas under ROC curve), and calibration curves were adopted to display the performance of this prognostic signature. In addition, immune infiltration analysis was implemented to evaluate the effect of these m7G genes on immunoinfiltrating cells. Correlation with drug susceptibility of the m7G signature was also analyzed by matching drug information in CellMiner database. Results. The m7G-related prognostic signature, including three genes (EIF3D, EIF4A1, LARP1) illustrated superior prognostic ability for PRAD in both training and validation cohorts. The 5-year AUC were 0.768 for TCGA-PRAD and 0.608 for GSE116918. It can well distinguish patients into different risk groups of biochemical recurrence ( =1e-04 for TCGA-PRAD and =0.0186 for GSE116918). Immune infiltration analysis suggested potential regulation of m7G genes on neutrophils and dendritic cells in PRAD. Conclusions. A m7G-related prognostic signature was constructed and validated in the current study, giving new sights of m7G methylation in predicting the prognostic and improving the treatment of PRAD.

1 April 2022 in Bioengineered
Verified
Journal Article
Open access
KWKeyi Wang
Keyi Wang
YGYongzhe Gu
Yongzhe Gu
JNJinliang Ni
Jinliang Ni
HZHouliang Zhang
Houliang Zhang
YWYidi Wang
Yidi Wang
BPBo Peng
Bo Peng
Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant kidney tumors with a poor prognosis. Accumulating evidence proves that zinc finger protein 268 (ZNF268) is associated with tumor progression, but the detailed regulatory functions of ZNF268 in ccRCC require further exploration. Thus, here we aim to characterize the role of ZNF268 in ccRCC. The clinical significance of ZNF268 was evaluated using The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases. Subsequently, tumor-infiltrating immune cells, as well as upstream noncoding RNAs (ncRNAs) related to the tumor-suppressing function of ZNF268, were identified by in silico analyses. The expression of ZNF268 was significantly decreased in ccRCC samples compared with adjacent normal tissues. In addition, ZNF268 expression was negatively correlated with tumor progression and positively correlated with overall and disease-specific survival. TCGA and GTEx databases proved the potential tumor-suppressing function, which was measured both in vitro and in vivo after ZNF268 over-expression. Overexpression of ZNF268 effectively inhibited the proliferation, migration, invasion and promotied apoptosis of the Caki-1. The level of ZNF268 was positively related to the immune cell infiltration in the tumor. Moreover, we determined that the AC093157.1/miR-27a-3p axis can potentially regulate ZNF268 function in ccRCC. Our work describes a novel ncRNA-mediated ZNF268 function in ccRCC. ZNF268 acts as a tumor suppressor, and it is associated with apoptosis and immune cell infiltration in ccRCC. Graphical abstract

17 March 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
SXShiyong Xin
Shiyong Xin
XSXianchao Sun
Xianchao Sun
LJLiang Jin
Liang Jin
ZZZhen Zhou
Zhen Zhou
XLXiang Liu
Xiang Liu
LYLin Ye
Lin Ye
The platelet-derived growth factor (PDGF) pathway is important in angiogenesis, which can accelerate the formation of vessels in tumor tissues and promote the progression of malignant tumors. To clarify the role of PDGF in the occurrence of renal cell carcinoma and targeted drug resistance, we explored the pathway in kidney renal clear cell carcinoma (KIRC) through bioinformatics analysis with the aim of supporting comprehensive and individualized therapy. First, we found 40 genes related to the PDGF pathway through gene set enrichment analysis and then obtained their expressions and clinical data in 32 different cancers from The Cancer Genome Atlas (TCGA). Mutations in these genes (including copy number and single-nucleotide variation) and mRNA expression were also detected. Next, we conducted a hazard ratio analysis to determine whether the PDGF pathway genes were risk or protective factors in tumors. Although PDGF-related genes acted as traditional oncogenes and were closely related to tumor angiogenesis in many cancers, our results indicated that most genes had a protective role in KIRC. We further analyzed the methylation modification of PDGF pathway genes and found that they were prevalent in 32 different cancers. Furthermore, 539 KIRC samples obtained from TCGA were divided into three clusters based on the mRNA expression of PDGF genes, including normal, inactive, and active PDGF gene expressions. The results from survival curve analysis indicated that the active PDGF cluster of patients had the best survival rate. Using the three clusters, we studied the correlation between the PDGF pathway and 12 common targeted drugs, as well as classical oncogenes and infiltrating immune cells. A prognostic risk model was constructed based on the PDGF score using LASSO-Cox regression analysis to analyze the value of the model in predicting the prognosis of patients with KIRC. Finally, 11 genes were selected for LASSO regression analysis, and the results demonstrated the high predictive value of this risk model and its close relationship with the pathological characteristics of KIRC (metastasis, size, grade, stage, etc.). In addition, we found that the risk score was an independent risk factor correlated with overall survival through univariate and multivariate analyses and a nomogram was built to assess patient prognosis. In conclusion, the occurrence and development of KIRC may be associated with an abnormally activated PDGF pathway, which may be a potential drug target in the treatment of KIRC.

1 January 2025 in Andrologia
Verified
Journal Article
Open access
WZWei Zhang
Wei Zhang
XSXianchao Sun
Xianchao Sun
HGHao Geng
Hao Geng
TZTao Zhou
Tao Zhou
JCJing Chang
Jing Chang
CZCi Zou
Ci Zou
Background: The alteration of sleep patterns can lead to bias in the observation of nocturnal penile tumescence and rigidity (NPTR). The validity of sleep‐related erections (SREs) is questioned when sleep quality is affected. Not all NPTR results accurately reflect the reality of ED patients. Objectives: The present study aims to simultaneously monitor sleep and NPTR monitoring in patients with erectile dysfunction (ED), thereby evaluating the effect of sleep on NPTR monitoring and validating the reliability of NPTR monitoring data obtained from RigiScan. Methods: The present study recruited patients who had an International Index of Erectile Function‐5 (IIEF‐5) score ≤21 and had ED greater than 6 months duration. Then all participants were subjected to the following: NPTR assessment utilizing RigiScan devices; sleep assessment using a Fitbit Charge 2 wristband. Results: Eighty‐six patients (age 29.8 ± 7.09 and BMI 24.3 ± 3.62) with complaints of ED were included. Stratification analysis showed that patients with abnormal NPTR results had a shorter total sleep time (TST) and time in rapid eye movement (REM). The duration of tip erections ≥60% of the men with short TST was significantly longer than the not short group. The results showed that the time in REM of population with was positively correlated with the TST and the duration of NPTR. A receiver operating characteristic (ROC) curve analysis was performed between the normal and the abnormal NPTR groups, and the parameter with the highest diagnostic accuracy was the time in REM. Conclusion: Our study confirmed that sleep states comprising TST and REM are closely related to nocturnal erection. It is necessary to perform sleep monitoring when completing NPTR examinations for patients suspected of suffering from ED.